For those living with inflammatory bowel disease (IBD), the battle for a good night's sleep is proving to be an inflammatory issue and not simply a symptom of the condition. Recent findings from a study published in Clinical Gastroenterology and Hepatology have shown that sleep disturbances in IBD patients are primarily linked to inflammation, rather than symptomatic flares that were previously thought to be the culprit.
Sleep architecture, which is essentially how we cycle through different stages of sleep, from light sleep to REM, has been found to be impaired in patients with IBD when inflammation levels are elevated. The recent findings are based on an analysis supported by data collected from wearable technology and fitness trackers. These modern-day gadgets are monitoring long-term sleep patterns and providing researchers with a clearer picture of what's really disturbing the sleep of IBD sufferers. Despite the common understanding that symptoms might play a more prevalent role in sleep disruption, the study indicates otherwise, challenging prior assumptions and pointing towards inflammation as the main sleep-disrupting factor in IBD patients.
Dr. Susan Kais, a board-certified gastroenterologist and assistant professor from the University of Cincinnati College of Medicine, shared insights in a MedCentral article on the significance of the study's approach, saying via UC News, "In addition, the study was then able to overlap these assessments with both symptomatic and inflammatory data more readily." Though not directly involved in the study, Kais supports the notion that treating inflammation should be a priority for clinicians in addressing sleep disturbances in IBD patients.
What's coming to light is a different approach to treating this facet of IBD, it's not just about managing symptoms on the surface but digging deeper into the inflammatory aspects that could provide relief. Kais offered advice for healthcare professionals, arguing for the importance of considering sleep disturbances as a critical metric in IBD care by saying, through UC News, "As clinicians, we may be overlooking sleep disturbances as an important IBD metric that should be assessed more routinely." She suggests "More frequent monitoring of inflammatory markers, such as C-reactive protein and fecal calprotectin, alongside the integration of wearable sleep technology devices, can detect disturbances early and guide timely, sleep-related interventions," a statement which circles back to the study's emphasis on inflammation over symptomatic flare-ups. With these new revelations, hope is on the horizon for both clinicians and patients aiming for undisturbed slumber despite the challenges of IBD.
